Skip to main content
Health & Medicine

Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.

| Source: Lancet (London, England)

The R21/Matrix-M (R21) malaria vaccine candidate, recommended by WHO for use in young children, could be extended to the whole population. Seasonal mass vaccination (SMV) before peak malaria transmission could be a promising tool to accelerate progress towards malaria elimination. We aimed to evaluate the safety and effectiveness of SMV with R21 in two malaria-endemic settings in west Africa. This open-label, cluster-randomised, controlled trial was conducted in The Gambia, a setting with low-to

The R21/Matrix-M (R21) malaria vaccine candidate, recommended by WHO for use in young children, could be extended to the whole population. Seasonal mass vaccination (SMV) before peak malaria transmission could be a promising tool to accelerate progress towards malaria elimination. We aimed to evaluate the safety and effectiveness of SMV with R21 in two malaria-endemic settings in west Africa. This open-label, cluster-randomised, controlled trial was conducted in The Gambia, a setting with low-to-moderate seasonal transmission, and Burkina Faso, a setting with intense seasonal transmission. 54 medium-sized villages (30 in The Gambia and 24 in Burkina Faso) were randomly assigned (1:1) by use of computer-restricted randomisation to receive either SMV with R21 (intervention group) or no SMV (control group). All study villages received national standard malaria control interventions. In the intervention group, residents who were aged 5 months and older, willing to comply with trial procedures, and could provide written informed consent (from parents or guardians for children aged <18 years plus assent for children aged 12-17 years) were eligible for vaccination. The intervention was delivered as three monthly doses of 5 μg (participants aged <15 years) or 10 μg (participants aged ≥15 years) R21 plus 50 μg of Matrix-M. The primary outcome was malaria prevalence at peak transmission, defined as the proportion of participants with Plasmodium falciparum infection assessed by quantitative PCR. This trial is registered with ClinicalTrials.gov (NCT06578572) and the Pan-African Clinical Trials Registry (PACTR202404544467702), and is ongoing. The intervention was delivered between May 30, and Aug 21, 2024. A cross-sectional survey to estimate the primary endpoint was conducted between Nov 18 and Dec 6, 2024. The population available for vaccination varied across the three rounds. In The Gambia, among 4311 total residents in intervention villages, 2565 (59·5%) received three vaccine doses; in Burkina Faso, among 6235 total residents in intervention villages, 4072 (65·3%) received three vaccine doses. SMV with R21 reduced the odds of malaria infection by 70% (adjusted odds ratio 0·30 [95% CI 0·20-0·44]; p<0·0001) in The Gambia and by 25% (0·75 [95% CI 0·58-0·98]; p=0·036) in Burkina Faso. In The Gambia, prevalence decreased across all age groups, whereas in Burkina Faso the largest effect was observed in children younger than 5 years. The vaccine was safe and well tolerated. 651 adverse events were reported in 581 (13·5%) vaccine recipients in The Gambia, and 795 adverse events were reported in 705 (11·3%) vaccine recipients in Burkina Faso. Among 69 serious adverse events reported overall, only one was considered related to vaccination (febrile convulsions in a female participant aged 8 years after the second dose in The Gambia). SMV with R21 reduced malaria prevalence in both settings. It could become an additional strategy for malaria control in endemic areas of seasonal transmission. In low-to-moderate transmission settings, the vaccine could accelerate progress towards elimination; in high-transmission areas it could further reduce the malaria burden. UK Medical Research Council and the UK Foreign, Commonwealth & Development Office.

Read the original source →

Related Stories

Health & Medicine

Distinct nanoscale architectures of GABAergic inhibitory synapses predict diverse synaptic output.

GABAergic synaptic inhibition is heterogenous across neuronal compartments, and plays a critical role in shaping local, cellular, and circuit excitability. In pyramidal neurons, inhibition is mediated by GABA A receptors (GABA A Rs) clustered at the inhibitory postsynaptic domain (iPSD). Synaptic strength depends not only on the number of GABA A Rs within the iPSD, but also on their precise nanoscale organization into discrete subsynaptic domains (SSDs). These SSDs often align with presynaptic G

Continue reading
Health & Medicine

Leptin Receptor + cells create a perisinusoidal niche for thrombopoiesis in the bone marrow by synthesizing CXCL14.

Leptin Receptor-expressing (LepR + ) stromal cells in the bone marrow are a critical source of growth factors for the maintenance of hematopoietic stem cells (HSCs) and most restricted hematopoietic progenitors. An important unresolved question is whether they also regulate terminal differentiation in some hematopoietic cells. We found that bone marrow LepR + cells promote thrombopoiesis by synthesizing the chemokine CXCL14. Cxcl14 -expressing LepR + cells extend fine processes that wrap around

Continue reading
Health & Medicine

SCN1B intron 3 retention results in a nonsense-mediated decay-sensitive mRNA linked to developmental and epileptic encephalopathy.

Biallelic variants in the voltage-gated sodium channel (VGSC) gene SCN1B are linked to developmental and epileptic encephalopathy type 52 (DEE52). SCN1B encodes two isoforms: transmembrane β1, generated by all 6 coding exons, and β1B, generated by exons 1 to 3 followed by retention of intron 3 ( SCN1B -IR). Transmembrane β1 subunits are multifunctional proteins that regulate sodium current and channel cell-surface expression, participate in cell-cell and cell-matrix adhesion, a

Continue reading
Health & Medicine

Anomeric configuration encodes mesophase preference of glucosylceramides in phospholipid membranes.

Glycosphingolipids are key components of the cell glycocalyx, yet the extent to which their anomeric configuration affects their membrane organization remains unclear. Glucosylceramide (GlcCer) exists as α- and β-anomers with distinct biological activities, while the biophysical basis for these differences is unknown. Here, using nitroxide spin-labeled analogs of α- and β-GlcCer, we examined how the glycosidic stereochemistry affects their partitioning in phospholipid bil

Continue reading
Health & Medicine

A genome-wide senescence synthetic lethality screen identifies PARP16 as a senolytic target.

Accumulation of senescent cells is increasingly viewed as a significant contributor to aging and age-related diseases. To date, the elimination of senescent cells through small molecule senolytic agents has largely relied on a limited number of repurposed agents, often leveraged from previous oncological applications. Here, we describe a CRISPR-based, genome-wide, synthetic lethal screen for senescent cells. From this screen, we identify a number of genes whose deletion appears to be well tolera

Continue reading